JIYUN PANG1,2,#, WEIGANG XIU1,#, YUEYUN CHEN4, WENJING LIAO1,2, QIN ZHANG3,*, HUASHAN SHI4,*
Oncology Research, Vol.33, No.4, pp. 895-904, 2025, DOI:10.32604/or.2024.053363
- 19 March 2025
Abstract Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable… More >